Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NASDAQ:IFRX NASDAQ:KALA NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.99+5.9%$1.69$0.95▼$3.19$71.54M0.1372,770 shs599,362 shsIFRXInflaRx$1.60+36.8%$0.88$0.71▼$2.82$107.41M1.29370,771 shs4.12 million shsKALAKALA BIO$11.22+5.9%$6.89$2.92▼$11.68$78.78M-1.81122,558 shs404,474 shsMBRXMoleculin Biotech$0.39-0.2%$0.56$0.25▼$3.65$11.88M1.393.73 million shs4.72 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+1.02%+36.30%+12.11%+49.62%IFRXInflaRx0.00%+75.15%+76.80%+98.76%-0.62%KALAKALA BIO0.00%+21.82%+65.73%+205.72%+90.17%MBRXMoleculin Biotech0.00%-30.87%-37.52%-56.23%-84.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGANXGain Therapeutics2.1167 of 5 stars3.53.00.00.02.20.00.6IFRXInflaRx2.9742 of 5 stars3.54.00.00.03.81.70.0KALAKALA BIO3.4797 of 5 stars2.52.00.04.43.30.80.6MBRXMoleculin Biotech2.9232 of 5 stars3.54.00.00.02.41.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 3.00Buy$7.80291.96% UpsideIFRXInflaRx 3.00Buy$6.60312.50% UpsideKALAKALA BIO 3.00Buy$13.0015.86% UpsideMBRXMoleculin Biotech 3.00Buy$4.00919.37% UpsideCurrent Analyst Ratings BreakdownLatest MBRX, GANX, IFRX, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.008/13/2025GANXGain TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,430.81N/AN/A$0.10 per share19.90IFRXInflaRx$180K596.71N/AN/A$0.96 per share1.67KALAKALA BIO$3.89M20.25N/AN/A($0.46) per share-24.39MBRXMoleculin BiotechN/AN/AN/AN/A($0.24) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%11/13/2025 (Estimated)IFRXInflaRx-$49.85M-$0.80N/AN/AN/AN/A-71.76%-57.68%11/14/2025 (Estimated)KALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-1,498.41%-114.47%11/14/2025 (Estimated)Latest MBRX, GANX, IFRX, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GANXGain Therapeutics-$0.17-$0.19-$0.02-$0.19N/AN/A8/12/2025Q2 2025MBRXMoleculin Biotech-$0.39-$0.49-$0.10-$0.49N/AN/A8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/7/2025Q2 2025IFRXInflaRx-$0.24-$0.24N/A-$0.24$0.02 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.091.791.79IFRXInflaRxN/A4.103.78KALAKALA BIO3.192.102.10MBRXMoleculin BiotechN/A1.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%IFRXInflaRx42.39%KALAKALA BIO24.61%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics7.18%IFRXInflaRx16.30%KALAKALA BIO8.32%MBRXMoleculin Biotech2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2035.95 million33.37 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableKALAKALA BIO307.02 million6.44 millionNot OptionableMBRXMoleculin Biotech2030.29 million29.65 millionNot OptionableMBRX, GANX, IFRX, and KALA HeadlinesRecent News About These CompaniesMoleculin Biotech Completes Promising Annamycin TrialAugust 29 at 11:49 PM | msn.comMoleculin Biotech announces OS data from Phase 1B/2 clinical trial in AMLAugust 28 at 1:55 PM | msn.comMoleculin Announces Exercise of Warrants for $6.0 Million Gross ProceedsAugust 28 at 8:30 AM | globenewswire.comMoleculin Biotech's (MBRX) "Buy" Rating Reiterated at HC WainwrightAugust 28 at 3:33 AM | americanbankingnews.comMoleculin Issues New Positive AML Overall Survival Data:August 27, 2025 | globenewswire.comMoleculin Biotech Holds 2025 Annual Stockholders MeetingAugust 19, 2025 | msn.comMoleculin Biotech Releases New Corporate PresentationAugust 19, 2025 | msn.comMoleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comMoleculin Biotech Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comMoleculin Biotech reports Q2 EPS (49c) vs. ($1.70) last yearAugust 14, 2025 | msn.comMoleculin Biotech, Inc.: Moleculin Reports Second Quarter 2025 Financial Results and HighlightsAugust 14, 2025 | finanznachrichten.deMoleculin Biotech Misses Fiscal Q2 EPSAugust 14, 2025 | aol.comAMoleculin Biotech sees cash runway into Q4August 14, 2025 | msn.comMoleculin Reports Second Quarter 2025 Financial Results and HighlightsAugust 13, 2025 | globenewswire.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer ...August 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | gurufocus.comMoleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer TreatmentAugust 6, 2025 | globenewswire.comMoleculin Biotech Releases Corporate Presentation UpdateAugust 1, 2025 | tipranks.comMoleculin Biotech, Inc.: Moleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 31, 2025 | finanznachrichten.deMoleculin Receives Notice of Intent to Grant New European Patent for AnnamycinJuly 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBRX, GANX, IFRX, and KALA Company DescriptionsGain Therapeutics NASDAQ:GANX$1.99 +0.11 (+5.85%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.01 +0.02 (+1.21%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.InflaRx NASDAQ:IFRX$1.60 +0.43 (+36.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.70 +0.10 (+6.25%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.KALA BIO NASDAQ:KALA$11.22 +0.63 (+5.95%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$11.58 +0.37 (+3.25%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Moleculin Biotech NASDAQ:MBRX$0.39 0.00 (-0.18%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.40 +0.01 (+1.43%) As of 08/29/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
